The lawsuit, filed by a group of buyers in 2006, alleges Mylan delayed putting its generic version of Cephalon’s sleeping pill Provigil on the market in exchange for payment from Cephalon, according to the report.
Through the settlement, Mylan will offer buyers — defined as all persons or entities in the U.S. who bought Provigil directly from Cephalon between June 24, 2006, and Aug. 31, 2012 —their allocated share of the settlement fund, excluding legal fees, reports Bloomberg.
The agreement is still pending approval by U.S. District Judge Mitchell Goldberg.
More articles on supply chain:
Express Scripts: Drug spending slowed in 2016
Study: Amgen’s Repatha lowers risk of heart problems
Government subpoenas Biogen over MS drug prices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
